Allyson Parry
Overview
Explore the profile of Allyson Parry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
29
Citations
299
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Forde C, Smith M, Burghel G, Bowers N, Roberts N, Lavin T, et al.
J Med Genet
. 2024 Jun;
61(9):856-860.
PMID: 38925914
Objectives: New diagnostic criteria for NF2-related schwannomatosis (NF2) were published in 2022. An updated UK prevalence was generated in accordance with these, with an emphasis on the rate of de...
2.
Leaver L, Cubbin S, Parry A
Br J Gen Pract
. 2023 Nov;
73(737):540-541.
PMID: 38035824
No abstract available.
3.
Shrivastava M, Emmanouil B, Mathew R, Halliday D, Parry A, Halliday J, et al.
Laryngoscope
. 2023 Nov;
134(5):2364-2371.
PMID: 37983868
Objectives: To determine the long-term control rates and hearing outcomes for growing vestibular schwannoma in NF2-related schwannomatosis (NF2) treated with stereotactic radiosurgery (SRS) and fractionated radiotherapy (FRT). Methods: Retrospective review...
4.
Leaver L, Parry A, Cubbin S
Clin Med (Lond)
. 2023 Sep;
23(5):534.
PMID: 37775169
No abstract available.
5.
Evans D, Halliday D, Obholzer R, Afridi S, Forde C, Rutherford S, et al.
Neurooncol Adv
. 2023 Apr;
5(1):vdad025.
PMID: 37051330
Background: Radiation treatment of benign tumors in tumor predisposition syndromes is controversial, but short-term studies from treatment centers suggest safety despite apparent radiation-associated malignancy being reported. We determined whether radiation...
6.
Leaver L, Parry A, Read H
Clin Med (Lond)
. 2023 Jan;
23(1):100.
PMID: 36697007
No abstract available.
7.
Emmanouil B, Wasik M, Charbel Issa P, Halliday D, Parry A, Sharma S
Ophthalmic Res
. 2021 Oct;
65(1):77-85.
PMID: 34673638
Introduction: This case-control study seeks to systematically characterize the central retinal findings in a large cohort of patients with neurofibromatosis type 2 (NF2) using spectral domain optical coherence tomography (SD-OCT)...
8.
Brown J, May A, Crabtree R, Emmanouil B, Halliday D, Parry A, et al.
BMJ Open Qual
. 2021 Feb;
10(1).
PMID: 33632762
No abstract available.
9.
Cubbin S, Leaver L, Parry A
Br J Gen Pract
. 2020 Aug;
70(698):465-466.
PMID: 32855146
No abstract available.
10.
Halliday D, Parry A, Evans D
Curr Opin Oncol
. 2019 Aug;
31(6):562-567.
PMID: 31425178
Purpose Of Review: Neurofibromatosis type 2 (NF2) is a schwannoma predisposition syndrome, alongside schwannomatosis related to germline LZTR1 and SMARCB1 pathogenic variants. This review highlights their overlapping phenotypes, new insight...